Differences in biological behaviors and clinical treatment between colon and rectal cancers
10.3872/j.issn.1007-385X.2018.10.002
- VernacularTitle:结肠癌与直肠癌生物学行为及临床治疗的差异
- Author:
ZHAO Chengshuai
1
;
WANG Lei
2
;
WANG Mei
2
Author Information
1. Department of Oncology, Changhai Hospital, Second Military Medical University
2. （Department of Oncology, Changhai Hospital, Second Military Medical University
- Publication Type:Journal Article
- Keywords:
colon cancer;
rectal cancer;
biological behavior;
clinical treatment;
difference
- From:
Chinese Journal of Cancer Biotherapy
2018;25(10):979-986
- CountryChina
- Language:Chinese
-
Abstract:
At present, more and more evidence shows that colon and rectal cancers are different diseases. There are many differences no matter in the epidemiology, anatomy and histology, molecular characteristics, transfer patterns, or clinical treatment methods, therapeutic effects and prognosis. In clinical treatment, it cann’t be considered as the same disease in general. Through the retrospective analysis of the three clinical studies of CALGB/SWOG 80405, CRYSTAL, and FIRE-3, it has been found that there were significant differences in the efficacy of cetuximab and bevacizumab in left and right colon cancer. Based on the above clinical trials, the National Cancer Institute for the United States (NCCN) for the first time includes the guidelines for the impact of primary sites on the treatment of colon cancer into guidelines in 2017. In the current era of advocating precision and individualized treatment, to clarify the pathogenesis, histological differences and clinical response to drugs in colon cancer and rectal cancer, can not only reduce the economic burden of patients, but also provide the most scientific basis for the precise treatment of patients gradually.
- Full text:20181002.pdf
